Personalis Inc. has announced the publication of a new clinical study in the journal Clinical Cancer Research, evaluating the use of its ultra-sensitive, tumor-informed molecular residual disease (MRD) assay, NeXT Personal®, for monitoring cancer immunotherapy response across a range of solid tumors. The study, led by Dr. Rodrigo Toledo at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, analyzed 202 patients with stage IV solid tumors across 24 cancer types treated with immune checkpoint inhibitors and other immunotherapies. Key findings include high sensitivity of the test, with ctDNA detected in 98% of patients at baseline, and the prognostic value of early ctDNA dynamics. Patients who achieved durable molecular clearance of ctDNA for at least 180 days had 100% overall survival in the study, while early increases in ctDNA were associated with poor response to immunotherapy. The results have been published and are now available.